Literature DB >> 15752919

Management of diabetic dyslipidemia.

Maria Del Pilar Solano1, Ronald B Goldberg.   

Abstract

Identification and management of dyslipidemia is an important element in the multi-factorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol, predominance of small, dense low-density lipoprotein (LDL) particles, and average LDL cholesterol (LDL-C). Lipid-lowering therapy has a beneficial effect on cardiovascular outcomes. Statin treatment is beneficial in patients who are older than 40 years of age, irrespective of the LDL-C value. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions, such as diet, exercise, smoking cessation, weight loss, and improving glycemic control. Although statin therapy is recommended for most subjects, judicious use of combination therapy should be considered in the highest risk subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752919     DOI: 10.1016/j.ecl.2005.01.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  14 in total

1.  Quality of diabetes care at outpatient clinic, sultan qaboos university hospital.

Authors:  Sawsan Al-Sinani; Ali Al-Mamari; Nicolas Woodhouse; Omaiyma Al-Shafie; Fatima Amar; Mohammed Al-Shafaee; Mohammed Hassan; Riad Bayoumi
Journal:  Oman Med J       Date:  2015-01

2.  Suppression of Type-II Diabetes with Dyslipidemia and Nephropathy by Peels of Musa cavendish Fruit.

Authors:  Vijay Navghare; Shashikant Dhawale
Journal:  Indian J Clin Biochem       Date:  2016-02-03

Review 3.  Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.

Authors:  Abeer Anabtawi; Patrick M Moriarty; John M Miles
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

4.  Gender differences in the relationship between plasma lipids and fasting plasma glucose in non-diabetic urban Chinese population: a cross-section study.

Authors:  Jie Zheng; Yuzhen Gao; Yuejuan Jing; Xiaoshuang Zhou; Yuanyuan Shi; Yanhong Li; Lihua Wang; Ruiying Wang; Maolian Li; Chuanshi Xiao; Yafeng Li; Rongshan Li
Journal:  Front Med       Date:  2014-07-17       Impact factor: 4.592

Review 5.  Dyslipidemia in type 2 diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

6.  Antihyperglycemic, antihyperlipidemic and antioxidative potential of Prosopis cineraria bark.

Authors:  Nidhi Sharma; Veena Garg; Arpita Paul
Journal:  Indian J Clin Biochem       Date:  2010-05-27

7.  Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.

Authors:  Maulik R Patel; Kevinkumar A Kansagra; Devang P Parikh; Deven V Parmar; Hardik B Patel; Mayur M Soni; Uday S Patil; Harilal V Patel; Jaimik A Patel; Swagat S Gujarathi; Krupi V Parmar; Nuggehally R Srinivas
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

8.  Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

Authors:  Rajendra H Jani; Kevinkumar Kansagra; Mukul R Jain; Harilal Patel
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

9.  A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).

Authors:  Vikas Pai; A Paneerselvam; Satinath Mukhopadhyay; Anil Bhansali; Dinesh Kamath; V Shankar; Dhiraj Gambhire; Rajendrakumar H Jani; Shashank Joshi; Pankaj Patel
Journal:  J Diabetes Sci Technol       Date:  2014-01-16

10.  Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial.

Authors:  Majid Mohamadshahi; Masoud Veissi; Fatemeh Haidari; Ahmad Zare Javid; Fatemeh Mohammadi; Esmat Shirbeigi
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.